NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis $10.36 +0.09 (+0.88%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.02▼$10.9350-Day Range$6.81▼$10.3652-Week Range$5.99▼$12.44Volume149,930 shsAverage Volume173,816 shsMarket Capitalization$513.23 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aura Biosciences alerts: Email Address Aura Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.7% Upside$21.00 Price TargetShort InterestBearish8.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.80) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector748th out of 936 stocksBiological Products, Except Diagnostic Industry127th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Aura Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.49% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 18.9, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 11.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AURA. Previous Next 2.5 News and Social Media Coverage News SentimentAura Biosciences has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aura Biosciences this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.40% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aura Biosciences are expected to grow in the coming year, from ($1.80) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aura Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Aura Biosciences Stock (NASDAQ:AURA)Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More AURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AURA Stock News HeadlinesJuly 26 at 4:36 PM | msn.comHC Wainwright & Co. Initiates Coverage of Aura Biosciences (AURA) with Buy RecommendationJuly 25 at 7:24 AM | americanbankingnews.comAura Biosciences (NASDAQ:AURA) Now Covered by HC WainwrightJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | finance.yahoo.comAura Biosciences Invests in InstantGMP QMS for Clinical Research Quality AssuranceMay 30, 2024 | globenewswire.comAura Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)May 23, 2024 | globenewswire.comAura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024May 10, 2024 | finance.yahoo.comAura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial OverviewJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024May 9, 2024 | globenewswire.comAura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | finance.yahoo.comOne Aura Biosciences Insider Raised Stake By 232% In Previous YearMay 8, 2024 | globenewswire.comAura Biosciences to Participate in Upcoming Investor ConferencesApril 20, 2024 | msn.comFF16 Ultima Abilities And How To Unlock Them In The Rising TideMarch 29, 2024 | msn.com3 Best Stocks to Buy Now, 3/29/2024, According to Top AnalystsMarch 29, 2024 | markets.businessinsider.comAura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial HealthMarch 28, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)March 28, 2024 | finance.yahoo.comWe're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn RateSee More Headlines Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$23.00 Low Stock Price Target$19.00 Potential Upside/Downside+102.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.79% Return on Assets-36.47% Debt Debt-to-Equity RatioN/A Current Ratio21.97 Quick Ratio21.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book2.26Miscellaneous Outstanding Shares49,540,000Free Float46,868,000Market Cap$513.23 million OptionableNot Optionable Beta0.38 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Elisabet de los Pinos Ph.D. (Age 51)Founder, CEO, President & Director Comp: $795.3kMs. Julie B. Feder (Age 54)CFO, Secretary & Treasurer Comp: $505.45kMr. Patrick NealonSenior Vice President of Clinical Development OperationsDr. Bruce Brown M.D.Senior VP & Therapeutic Area Head of Urologic OncologyDr. Anthony Daniels M.D.Therapeutic Area Head of Ocular OncologyDr. Richard Mountfield Ph.D.Senior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsUrovant SciencesNASDAQ:UROVUroGen PharmaNASDAQ:URGNProQR TherapeuticsNASDAQ:PRQRPersonalisNASDAQ:PSNLInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 48,549 shares on 7/26/2024Ownership: 0.289%Values First Advisors Inc.Sold 9,167 shares on 7/19/2024Ownership: 0.037%Virtu Financial LLCBought 18,354 shares on 5/20/2024Ownership: 0.037%Levin Capital Strategies L.P.Bought 11,200 shares on 5/16/2024Ownership: 0.224%Price T Rowe Associates Inc. MDSold 64,152 shares on 5/15/2024Ownership: 1.202%View All Insider TransactionsView All Institutional Transactions AURA Stock Analysis - Frequently Asked Questions How have AURA shares performed this year? Aura Biosciences' stock was trading at $8.86 at the beginning of the year. Since then, AURA shares have increased by 16.9% and is now trading at $10.36. View the best growth stocks for 2024 here. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.11. When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Top institutional shareholders of Aura Biosciences include Bank of New York Mellon Corp (0.29%) and Values First Advisors Inc. (0.04%). Insiders that own company stock include Matrix Capital Management Comp, Los Pinos Elisabet De, Julie B Feder, Cadmus Rich and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AURA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
